Literature DB >> 7662305

Clinical issues in antibody design.

K A Chester1, R E Hawkins.   

Abstract

Antibody genes can now be cloned and expressed in various ways to give new versions of antibodies that possess reduced immunogenicity, improved affinity, altered size, increased avidity and novel effector functions. The task for any clinical application is, first, to define a relevant target, and then to design the optimal antibody-based therapeutic molecule to react with that target. This article reviews these improved antibody-based molecules and examines their role in cancer therapy.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7662305     DOI： 10.1016/S0167-7799(00)88968-4

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN： 0167-7799            Impact factor:   19.536


  9 in total

Review 1.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

Review 2.  Monoclonal antibodies in cancer therapy.

Authors:  R Gruber; E Holz; G Riethmüller
Journal:  Springer Semin Immunopathol       Date:  1996

Review 3.  Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.

Authors:  Egesta Lopci; Arturo Chiti; Maria Rita Castellani; Giovanna Pepe; Lidija Antunovic; Stefano Fanti; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

4.  Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.

Authors:  Subhash C Chauhan; Maneesh Jain; Erik D Moore; Uwe A Wittel; Jing Li; Peter R Gwilt; David Colcher; Surinder K Batra
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-02       Impact factor: 9.236

5.  Nanoparticle delivery of a peptide targeting EGFR signaling.

Authors:  Sang Kyoon Kim; Leaf Huang
Journal:  J Control Release       Date:  2011-08-17       Impact factor: 9.776

6.  Rice cell culture as an alternative production system for functional diagnostic and therapeutic antibodies.

Authors:  E Torres; C Vaquero; L Nicholson; M Sack; E Stöger; J Drossard; P Christou; R Fischer; Y Perrin
Journal:  Transgenic Res       Date:  1999       Impact factor: 2.788

Review 7.  Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges.

Authors:  Frank R Brennan; Leigh Shaw; Mark G Wing; Christine Robinson
Journal:  Mol Biotechnol       Date:  2004-05       Impact factor: 2.860

8.  Structural consensus among antibodies defines the antigen binding site.

Authors:  Vered Kunik; Bjoern Peters; Yanay Ofran
Journal:  PLoS Comput Biol       Date:  2012-02-23       Impact factor: 4.475

Review 9.  Fe₃O₄ Nanoparticles in Targeted Drug/Gene Delivery Systems.

Authors:  Lazhen Shen; Bei Li; Yongsheng Qiao
Journal:  Materials (Basel)       Date:  2018-02-23       Impact factor: 3.623
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.